Advancing Metabolic Drug Development: Integrated Preclinical Strategies from Discovery to IND-Enabling Studies

A webinar workshop on integrated preclinical strategies to support metabolic drug development from candidate selection through IND-enabling studies. The session covers how in vitro and in vivo pharmacology, DMPK, and nonclinical safety studies inform translational assessment and candidate progression. It also addresses design considerations for IND-enabling DMPK and toxicology programs and regulatory expectations for US and European submissions. Intended learning objectives include mapping nonclinical milestones and aligning study execution with regulatory requirements.

Instruction on best practices for integrating discovery, DMPK, and nonclinical safety strategies; guidance on designing IND-enabling studies; mapping of regulatory expectations and development milestones.

Intended for metabolic disease drug discovery scientists, translational scientists and pharmacologists, DMPK/ADME/PK-PD scientists, toxicologists and nonclinical safety scientists, preclinical development scientists, regulatory strategists, and project leaders.

Register via the event registration link provided by the organizer.